JP Morgan Chase
CRXT

JP Morgan Chase’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

JP Morgan Chase’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,846
Closed -$42K – 7201
2021
Q3 		$42K Buy
+7,846
New +$70.5K ﹤0.01% 5888

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $290M AUM 21.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase's CRXT Position: Q4 2021 in Review

JP Morgan Chase sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q4 2021, closing a stake of 7,846 shares — an estimated $42K sold.

JP Morgan Chase first reported a position in CRXT in Q3 2021 and held it in 1 quarter. The position peaked at $42K in Q3 2021. 12 funds tracked by Wall St. Rank hold CRXT as of Q4 2021.

  • JP Morgan Chase reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 7,846 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q4 2021, an estimated $42K.
  • JP Morgan Chase first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • JP Morgan Chase's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $42K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.